JP2014521623A5 - - Google Patents

Download PDF

Info

Publication number
JP2014521623A5
JP2014521623A5 JP2014522067A JP2014522067A JP2014521623A5 JP 2014521623 A5 JP2014521623 A5 JP 2014521623A5 JP 2014522067 A JP2014522067 A JP 2014522067A JP 2014522067 A JP2014522067 A JP 2014522067A JP 2014521623 A5 JP2014521623 A5 JP 2014521623A5
Authority
JP
Japan
Prior art keywords
amino
pyrazol
pyrimidin
chloro
hydroxyethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014522067A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521623A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/064515 external-priority patent/WO2013014162A1/en
Publication of JP2014521623A publication Critical patent/JP2014521623A/ja
Publication of JP2014521623A5 publication Critical patent/JP2014521623A5/ja
Pending legal-status Critical Current

Links

JP2014522067A 2011-07-28 2012-07-24 Jak阻害剤としてのヘテロシクリルピリミジンアナログ Pending JP2014521623A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11175807 2011-07-28
EP11175807.4 2011-07-28
US201261635921P 2012-04-20 2012-04-20
US61/635,921 2012-04-20
PCT/EP2012/064515 WO2013014162A1 (en) 2011-07-28 2012-07-24 Heterocyclyl pyrimidine analogues as jak inhibitors

Publications (2)

Publication Number Publication Date
JP2014521623A JP2014521623A (ja) 2014-08-28
JP2014521623A5 true JP2014521623A5 (https=) 2015-09-10

Family

ID=47600533

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014522067A Pending JP2014521623A (ja) 2011-07-28 2012-07-24 Jak阻害剤としてのヘテロシクリルピリミジンアナログ

Country Status (9)

Country Link
US (1) US20140179664A1 (https=)
EP (1) EP2736901A1 (https=)
JP (1) JP2014521623A (https=)
KR (1) KR20140047092A (https=)
CN (1) CN103781780B (https=)
AU (1) AU2012288892B2 (https=)
BR (1) BR112014000360A2 (https=)
CA (1) CA2843195A1 (https=)
WO (1) WO2013014162A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
EP2909194A1 (en) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
EP3057956B1 (en) 2013-10-18 2021-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2015164614A1 (en) * 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
JP6854762B2 (ja) 2014-12-23 2021-04-07 ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド サイクリン依存性キナーゼ7(cdk7)の阻害剤
USRE50776E1 (en) 2015-03-27 2026-02-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
AU2016319125B2 (en) 2015-09-09 2021-04-08 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
BR112018006817A2 (pt) 2015-10-08 2018-10-23 Macrogenics Inc método de tratamento do câncer
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
SMT202100699T1 (it) 2016-06-16 2022-01-10 Denali Therapeutics Inc Pirimidin-2-ilammino-1h-pirazoli come inibitori di lrrk2 per l'uso nel trattamento di disturbi neurodegenerativi
JP7117029B2 (ja) * 2017-09-21 2022-08-12 北京賽特明強医薬科技有限公司 2-置換ピラゾールアミノ-4-置換アミノ-5-ピリミジンホルムアミド系化合物、組成物およびその使用
CN109535132B (zh) * 2017-09-21 2021-07-20 北京赛特明强医药科技有限公司 2-取代吡唑氨基-4-取代氨基-5-嘧啶甲酰胺类化合物、组合物及其应用
JP7307729B2 (ja) 2017-12-20 2023-07-12 ヤンセン ファーマシューティカ エヌ.ベー. メニン-mll相互作用のエキソ-アザスピロ阻害剤
EP3810132A4 (en) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
CN110734427B (zh) * 2018-07-20 2021-01-15 北京赛特明强医药科技有限公司 含烯基的嘧啶甲酰胺类化合物、组合物及其应用
CN110845476B (zh) * 2018-08-21 2022-11-18 上海和誉生物医药科技有限公司 一种高选择性csf1r抑制剂、其制备方法和在药学上的应用
EP3877371A4 (en) 2018-11-07 2022-07-27 Dana-Farber Cancer Institute, Inc. IMIDAZOPYRIDINE DERIVATIVES AND AZA-IMIDAZOPYRIDINE DERIVATIVES AS JANUS KINASE 2 INHIBITORS AND USES THEREOF
EP3876939A4 (en) 2018-11-07 2022-08-10 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
US12522583B2 (en) 2018-11-07 2026-01-13 Dana-Farber Cancer Institute, Inc. Benzimidazole derivatives and aza-benzimidazole derivatives as Janus kinase 2 inhibitors and uses thereof
WO2020118683A1 (en) * 2018-12-14 2020-06-18 Lynk Pharmaceuticals Co. Ltd. Benzamides of pyrazolyl-amino-pyrimidinyl derivatives, and compositions and methods thereof
US12281126B2 (en) 2018-12-28 2025-04-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
US11518758B2 (en) * 2019-05-10 2022-12-06 Deciphera Pharmaceuticals, Llc Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
PE20220597A1 (es) 2019-05-10 2022-04-22 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
PE20221083A1 (es) 2019-06-17 2022-07-05 Deciphera Pharmaceuticals Llc Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso
TW202525813A (zh) 2019-12-19 2025-07-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
WO2024239282A1 (zh) * 2023-05-24 2024-11-28 凌科药业(杭州)有限公司 一种药物组合物、外用制剂及其制备方法、应用
CN120917009A (zh) * 2024-01-26 2025-11-07 凌科药业(杭州)有限公司 一种吡唑基-氨基-嘧啶基衍生物的苯甲酰胺的晶型、制备方法及应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2280930C (en) 1997-02-12 2010-04-06 The Regents Of The University Of Michigan Protein markers for lung cancer and use thereof
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
EP1054004B1 (en) * 1997-12-15 2008-07-16 Astellas Pharma Inc. Novel pyrimidine-5-carboxamide derivatives
PT1154774E (pt) 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
KR100881105B1 (ko) 1999-11-05 2009-02-02 아스트라제네카 아베 Vegf 억제제로서의 퀴나졸린 유도체
DE60037345T2 (de) 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen
JP3663382B2 (ja) 2000-02-15 2005-06-22 スージェン・インコーポレーテッド ピロール置換2−インドリノン蛋白質キナーゼ阻害剤
CN101218229A (zh) * 2005-05-05 2008-07-09 阿斯利康(瑞典)有限公司 吡唑基-氨基取代的嘧啶及其在癌症治疗中的应用
PL1891446T3 (pl) 2005-06-14 2013-08-30 Cellzome Gmbh Sposób identyfikacji nowych związków oddziałujących z enzymami
GB0605691D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
ES2318616T3 (es) 2006-06-01 2009-05-01 Cellzome Ag Metodos para la identificacion de moleculas que interactuan con zap-70 y para la purificacion de zap-70.
WO2008009458A1 (en) 2006-07-21 2008-01-24 Novartis Ag 2, 4 -di (arylaminio) -pyrimidine-5-carboxamide compounds as jak kinases inhibitors
BRPI0622030A2 (pt) 2006-11-16 2014-04-22 Pharmacopeia Llc Derivados de purina 7-substituída, para imunossupressão
WO2008118822A1 (en) 2007-03-23 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
US7834024B2 (en) 2007-03-26 2010-11-16 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
CN101678215B (zh) 2007-04-18 2014-10-01 辉瑞产品公司 用于治疗异常细胞生长的磺酰胺衍生物
WO2008132502A1 (en) * 2007-04-25 2008-11-06 Astrazeneca Ab Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer
US20090274698A1 (en) 2007-07-06 2009-11-05 Shripad Bhagwat Combination anti-cancer therapy
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
CA2758614A1 (en) 2009-04-14 2010-10-21 Cellzome Limited Fluoro substituted pyrimidine compounds as jak3 inhibitors
CA2775009A1 (en) * 2009-10-20 2011-04-28 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors

Similar Documents

Publication Publication Date Title
JP2014521623A5 (https=)
JP2015500862A5 (https=)
JP2022534751A5 (https=)
JP2014531449A5 (https=)
RU2014130214A (ru) Пиримидин-2, 4-диаминовые производные в качестве ингибиторов киназы
JP2013508332A5 (https=)
RU2014152257A (ru) Гетероциклильные пиримидиновые аналоги в качестве ингибиторов tyk2
JP2016538313A5 (https=)
RU2008135690A (ru) Соединения и композиции в качестве ингибиторов протеинкиназы
JP2014526549A5 (https=)
HRP20191220T1 (hr) Disupstituirani oktahi-dropirolo[3,4-c]piroli kao modulatori oreksin receptora
RU2015101115A (ru) Гетероароматическое циклическое производное с алкильной разветвленной цепью
RU2018120330A (ru) Химерные соединения, осуществляющие нацеливание для протеолиза, и способы их получения и применения
JP2019530695A5 (https=)
JP2017530999A5 (https=)
JP2007519754A5 (https=)
JP2022500402A5 (https=)
RU2007132262A (ru) Соединения и композиции в качестве ингибиторов протеинкиназ
JP2013531074A5 (https=)
SI3074386T1 (en) New aminopyrimidine derivatives
IL263511A (en) 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors
RU2015121374A (ru) Ингибиторы alk-киназы
JP2015517566A5 (https=)
SI2638031T1 (en) Pyrazole aminopyrimidine derivatives as LRRK2 modulators
RU2018138047A (ru) Гетероциклические вещества - агонисты gpr119